Targeted and whole-genome sequencing for drug resistance and genetic relatedness inference of rifampicin-resistant Mycobacterium tuberculosis: an in-depth comparison

靶向测序和全基因组测序在利福平耐药结核分枝杆菌耐药性和遗传相关性推断中的应用:一项深入的比较研究

阅读:1

Abstract

BACKGROUND: Challenges in tuberculosis (TB) control have fuelled interest in routine next generation sequencing (NGS). However, the comparative performance of targeted NGS (tNGS) and whole genome sequencing (WGS) for drug resistance and genetic relatedness inference remains unclear. METHODS: In this cross-sectional study, we compared WGS (MICK-MAGMA platform) and the Deeplex MycTB tNGS assay in 90 patients with rifampicin-resistant TB in South Africa. A pairwise analysis was conducted for a total of 60 isolates, for which tNGS was conducted directly on DNA from sputum, and WGS on cultured isolates from the same samples. RESULTS: Drug resistance inference was highly concordant (≥92%) for most drugs, but lower for isoniazid (82%) and ethionamide (78%). Mixed infections were more commonly detected in tNGS (6.7%) than WGS (1.7%), though likely due to analytical errors. tNGS detected more minor variants (allelic frequency <25%) than WGS (76 versus 32), with minimal overlap. Most minor variants were of unknown significance; some likely stemmed from contamination or sequencing errors. Heteroresistance involving minor variants was rare (4.7% in tNGS, 0% in WGS). WGS provided lineage and sublineage information for all samples, while tNGS reported lineage for 67% and sublineage for 20%. WGS classified more samples as genetically unrelated (76%) than tNGS (40%). CONCLUSION: In this cohort, drug resistance inference was largely concordant between tNGS and WGS. WGS offered higher resolution for genetic relatedness, while tNGS showed greater sensitivity for minor variants. Further research is needed to clarify the clinical relevance of minor variants and assess the utility of WGS for transmission control.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。